Pharma Journalist -

Superluminal Medicines has raised $60 million in an oversubscribed Series B financing to advance its drug development programs, including a lead treatment for rare genetic forms of…
Read More...

Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in adults with relapsing multiple sclerosis (RMS). The oral…
Read More...

Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical to support the research and development of a fully human VHH antibody for…
Read More...

Typewriter Therapeutics has emerged from stealth with $56 million in Series A financing to develop genetic medicines for cancer, autoimmune diseases, and severe genetic disorders.…
Read More...

The World ADC Awards 2026 shortlist has been announced, recognizing the organizations, teams, technologies, and individuals driving innovation and advancing the field of antibody-drug…
Read More...

Cipla Limited and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing and supply agreement for TQB2102, an…
Read More...

The U.S. Food and Drug Administration (FDA) has approved PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making…
Read More...

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced a shared commitment with the Trump Administration to explore ways to lower the cost of…
Read More...

Kazia Therapeutics Limited has closed an oversubscribed public offering that generated approximately $40 million in upfront gross proceeds, providing additional funding for the clinical…
Read More...

SK Biopharmaceuticals has agreed to in-license opakalim, an investigational anti-seizure medicine from Biohaven, in a deal that could reach $795 million and could help the South Korean…
Read More...